Monte Rosa Therapeutics (GLUE) Interest Expenses (2020 - 2026)

Monte Rosa Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $122.6 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 1566.3% year-over-year to $122.6 million in Q1 2026; TTM through Mar 2026 was $122.6 million, a 1566.3% increase from a year earlier, with the FY2025 full-year figure at $115.2 million, up 59.71% from the prior year.
• Interest Expenses grew to $122.6 million in Q1 2026 per GLUE's latest filing, from $115.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $122.6 million in Q1 2026 and bottomed at $7.4 million in Q1 2025.
• The 5-year median for Interest Expenses is $54.5 million (2023), against an average of $52.1 million.
• Across the five-year window, Interest Expenses plunged 89.05% in 2025 and surged 1566.3% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $33.1 million in 2022, then surged by 64.63% to $54.5 million in 2023, then sank by 79.03% to $11.4 million in 2024, then jumped by 909.24% to $115.2 million in 2025, then climbed by 6.42% to $122.6 million in 2026.
• Per Business Quant, the three latest GLUE Interest Expenses figures stand at $122.6 million (Q1 2026), $115.2 million (Q4 2025), and $15.9 million (Q3 2025).